Tumor necrosis factor inhibitory agents are currently considered to be contraindicated in psoriatic patients with hepatitis B.
We aim to provide guidance to dermatologists on the use of tumor necrosis factor inhibitor therapy in these patients.
The current literature was reviewed regarding the use of tumor necrosis factor-alpha inhibitory agents (etanercept, adalimumab, and infliximab) in psoriatic patients with particular reference to hepatitis B infection.
Tumor necrosis factor-alpha inhibitor therapy may result in reactivated hepatitis B in hepatitis B surface antigen-positive patients with psoriasis. This also occurs, although less frequently in patients with an isolated positive hepatitis B core antibody. Thus, all psoriasis patients should be screened for hepatitis B surface antigen plus hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy. Infliximab has been associated with more reactivation cases than the other 2 agents and fatalities have been reported with this agent. Evidence is presented that the risk of reactivation can be greatly minimized or eliminated by early or pre-emptive antiviral therapy.
The data is largely based on small case series that are retrospective in nature.
Hepatitis B screening is essential prior to the initiation of tumor necrosis factor-alpha inhibitor therapy. Psoriatic patients found to be hepatitis B surface antigen or hepatitis B core antibody-positive should be referred to an appropriate specialist for evaluation and therapy. This would allow for the safe use of tumor necrosis factor-alpha inhibitors in psoriatic patients despite recently published guidelines to the contrary.Le texte complet de cet article est disponible en PDF.
Key words : chronic hepatitis B, hepatitis B virus, liver function tests, psoriasis, tumor necrosis factor-alpha inhibitor
Abbreviations used : Anti-HBc, Anti-HBs, ALT, HBcAg, HBeAg, HBsAg, HBV, INF, Th1, TNF
| Funding sources: None.
| Disclosure: Dr Menter served on the advisory board and was a consultant, investigator, and speaker for Abbott Labs, Amgen, and Centocor, receiving grants and honoraria; served on the advisory board and was an investigator and consultant for Cephalon and UCB, receiving grants and honoraria; was a consultant, investigator, and speaker for Warner Chilcott and Wyeth, receiving honoraria; served on the advisory board and was an investigator for Galderma and Genentech, receiving grants and honoraria; was a consultant and investigator for Allergan and Astellas, receiving grants and honoraria; was an investigator for Collagenex, CombinatoRx, Dow, Ferndale, Leo, Medicis, Photocure, Pierre Fabre, 3M Pharmaceuticals, and XOMA, receiving grants; and was an investigator for Connetics, receiving grants and honorarium. Dr Perrillo currently serves on the hepatitis B advisory board of Roche Pharmaceuticals and is on the speaker’s bureau for Gilead Sciences and Bristol Myers Squibb. He has in the past received grant support from Bristol Myers Squibb and Roche Pharmaceuticals. He is the current Chair of the American Association for the Study of Liver Diseases Hepatitis B Special Interest Group. Dr Abramson has no conflicts of interest to declare.
| Reprints not available from the authors.